Caspase-1 and Lung Cancer: The Inflammatory Enzyme Scientists Are Targeting for Prevention
Caspase-1 is an enzyme best known for driving inflammation inside the body, and new research suggests it may also be a key driver of lung cancer development, and a promising new target for preventing it. A 2026 study led by researchers at MIT found that caspase-1 activity is elevated in developing lung tumors, and that blocking it, especially alongside an existing anti-inflammatory antibody, significantly reduced tumor formation in high-risk animal models. Because caspase-1 sits inside a broader inflammatory pathway implicated in several cancers, understanding what it does and where else it shows up in cancer research matters well beyond the lungs.
What Is Caspase-1?
Caspase-1 is a protease, an enzyme that works by cutting other proteins into active or inactive pieces. Its primary job in the body is to activate interleukin-1 beta (IL-1 beta), a powerful inflammatory signaling molecule, by splitting it into its mature, active form. Caspase-1 does this as part of a cellular structure called the inflammasome, a molecular complex that assembles in response to infection, injury, or cellular stress and triggers inflammation as well as a form of cell death called pyroptosis.
Pyroptosis is a highly inflammatory type of programmed cell death, distinct from the more familiar process of apoptosis. Where apoptosis tends to clear cells quietly, pyroptosis is explosive: it ruptures the cell and spills inflammatory signals into surrounding tissue. That inflammatory spillover is useful for fighting infection, but when it happens repeatedly or in the wrong context, it can create the kind of chronic inflammation that is increasingly recognized as a driver of cancer development.
The Caspase-1 and Lung Cancer Connection
Caspase-1 activity is elevated in developing lung tumors, according to a 2026 study published in Science Advances and led by researchers affiliated with MIT's Koch Institute. The connection traces back to an earlier clue: the 2017 CANTOS clinical trial, which tested an antibody that blocks IL-1 beta for cardiovascular disease, and unexpectedly found that patients who received it also had notably lower rates of lung cancer and lung cancer deaths. That surprising result pointed researchers toward the IL-1 beta inflammatory pathway, and caspase-1, as the enzyme responsible for activating it, as a potential lever for lung cancer prevention.
To confirm the connection, researchers used nanosensor technology, engineered nanoparticles designed to reveal which proteases are actively cutting proteins inside tissue, in mice genetically engineered to develop lung tumors driven by p53 and KRAS mutations, two of the most common mutations found in human lung cancer. Caspase-1 activity showed up concentrated specifically at tumor sites in untreated mice that went on to develop cancer, while mice treated with an IL-1 beta-blocking antibody had both lower caspase-1 activity and fewer tumors. Elevated caspase-1 activity was also detected in lung fluid samples from human lung cancer patients, reinforcing that the finding isn't limited to mouse models.
Can Blocking Caspase-1 Help Prevent Lung Cancer?
In the same study, researchers tested a small-molecule caspase-1 inhibitor, a drug that has already been through human safety trials for rheumatoid arthritis, repurposing it as a potential lung cancer prevention strategy. In the high-risk mouse model, animals given both the caspase-1 inhibitor and an IL-1 beta-blocking antibody together saw the strongest effect: nearly 20% of the treated mice never developed a lung tumor at all. Mice given either treatment alone still developed tumors, but they were significantly fewer and smaller than those in untreated animals.
This is early, preclinical research, not an approved cancer treatment or prevention drug. But because the caspase-1 inhibitor tested is an oral small molecule that has already cleared human safety studies for a different condition, it's considered a strong candidate for faster movement into human cancer-prevention trials compared to a therapy starting from scratch. Researchers see particular potential for people at elevated lung cancer risk, such as long-term smokers or those with precancerous lung nodules, as a group who might benefit most from a preventive rather than treatment-stage approach.
Other Cancers Caspase-1 Research May Help
Lung cancer is where caspase-1 has the newest and most direct prevention data, but it's part of a broader inflammasome pathway that researchers have linked to several other cancer types. The relationship is often complex; caspase-1 and the inflammasome can promote or suppress tumor growth depending on the specific cancer, stage, and tissue context, which is an active area of ongoing research rather than a settled picture. Cancers where caspase-1 or the related NLRP3 inflammasome pathway have shown notable research relevance include:
Hepatocellular carcinoma (primary liver cancer), where caspase-1 and inflammasome signaling have been studied for their role in the tumor microenvironment. Melanoma, where studies have found that serum caspase-1 levels correlate with tumor burden and treatment response in patients with metastatic disease. Colorectal cancer, one of the most extensively studied cancers in inflammasome and pyroptosis research, given the gut's close relationship with inflammatory signaling. Bladder and prostate cancer, grouped as urogenital cancers where the NLRP3 inflammasome has been shown to play a dual, context-dependent role in tumor progression. Oral cancer, where NLRP3 inflammasome activity and its regulation by microRNAs are an emerging research focus. Gastric and pancreatic cancers, where inflammasome-driven chronic inflammation is being studied as a contributing factor to tumor development.
Across these cancer types, caspase-1 is best understood right now as a research target and a biomarker of interest, not as something with an approved caspase-1-targeted cancer drug on the market. The lung cancer prevention data is the furthest along, but the broader pattern is prompting researchers to ask the same question across other inflammation-linked cancers: could interrupting this pathway earlier change a patient's risk?
Frequently Asked Questions
What does caspase-1 do in the body? Caspase-1 is an enzyme that activates the inflammatory molecule IL-1 beta and drives pyroptosis, an inflammatory form of cell death. It plays a central role in the body's innate immune response to infection and injury.
Is there an approved caspase-1 inhibitor drug for cancer? Not yet. A small-molecule caspase-1 inhibitor has completed human safety trials for rheumatoid arthritis, and researchers are now studying whether it could help prevent lung cancer in high-risk patients, but it is not currently approved for any cancer-related use.
Does caspase-1 cause cancer or help fight it? Both are possible, depending on context. In developing lung tumors, elevated caspase-1 activity appears to promote cancer development through chronic inflammation. In other settings, the inflammasome pathway it belongs to can also contribute to immune responses against tumors, which is why researchers describe its role as context-dependent.
Who might benefit most from caspase-1-targeted lung cancer prevention research? Early discussion has focused on people at elevated lung cancer risk, such as long-term smokers or those with precancerous lung nodules identified on imaging, though this remains preclinical research and not an available treatment.
What other cancers is caspase-1 being studied in? Beyond lung cancer, research has examined caspase-1 and the related NLRP3 inflammasome pathway in hepatocellular carcinoma, melanoma, colorectal cancer, bladder and prostate cancer, oral cancer, and gastric and pancreatic cancers.
The Bottom Line
Caspase-1 is emerging as one of the more promising leads in cancer prevention research, an inflammatory enzyme with a direct line to a cytokine already tied to lung cancer risk in human clinical trial data. The path from a mouse study to an approved prevention strategy is still long, but the combination of a validated biological mechanism, a drug that has already cleared human safety testing for another condition, and a growing list of other cancers where the same inflammatory pathway shows up, makes this a space worth watching. As always, anyone concerned about their personal cancer risk should talk with their care team about currently available screening and prevention options.
